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 Accurate genotyping of the human leukocyte antigens (HLA) are crucial for the 
success of hematopoietic stem cell and solid organ transplantation. Over the past 50 years, 
numerous methodologies have been used for HLA typing but technological limitations 
have prevented full interrogation of the HLA gene thus resulting in allelic ambiguity. In 
order to resolve these ambiguities, additional testing is often required, leading to increased 
expense and delay in reporting the genotyping results. Recently, advances in nucleic acid 
sequencing technologies, generally referred to as next-generation sequencing (NGS), have 
become available. HLA genotyping by NGS is poised to become the new gold standard for 
several reasons. First, the entire gene can be interrogated, as opposed to a few exons, thus 
enabling greater resolution of known polymorphisms outside of the T cell recognition site 
on the HLA molecule. Secondly, missing genetic sequences in the curated databases will 
become more complete thus improving the algorithms used for alignment to a reference 
sequence. Lastly, NGS will become the new gold standard because high-resolution 
genotyping can be achieved without the need for additional time and laboratory resources 
in order to resolve allelic ambiguities and meet typing requirements required by regulatory 
agencies. In this thesis I discuss my efforts to employ this new technology by developing 
an assay for genotyping of the HLA-A, B, C, DRB1, and DQB1 genes. In the new assay, 
98% of all alleles typed correctly and unambiguously without the need for any secondary 
testing. This in-house method is later compared with two recently released commercial kits 
iv 
and 100% concordance was found between the three methods.  Differences in workflow 
are compared and contrasted. In conclusion, we show that HLA genotyping by NGS 
produces more correct and unambiguous results than traditional Sanger sequencing without 
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The human leukocyte antigen (HLA) system is part of the major histocompatibility 
complex (MHC), a set of cell surface markers essential for the discrimination of self and 
foreign antigens.  The nature of its discovery is helpful in understanding its biology and 
function.  Three unrelated events were vital in its discovery in the early 1900s.  The first 
was the development and use of inbred mouse strains for scientific studies.  An early 
geneticist, C. C. Little, recognized the value in the use of genetically identical mouse strains 
and went on to establish Jackson Laboratories, which has since become the world’s 
foremost laboratories for these mice. The second event was interest in tumor 
transplantation in mice.  In 1916, Little and others began experimenting transferring tumors 
between various strains of mice. They found that tumors were usually rejected by different 
strains of mice but there was no rejection within inbred strains of mice (Little, 1916). The 
discovery of blood groups by Paul Ehrlich, J Morgenroth, and Karl Landsteiner (Klein, 
1986a) through the use of hemagglutination methods was another critical step. In 1933, J. 
B. S. Haldane, an English scientist, visited Little and the newly formed Jackson 
Laboratories and became acquainted with the work of the tumor transfer scientists. He, 
along with three pairs of inbred mice, returned to England and suggested to his colleague, 
Peter Gorer, that gene products affecting the reactions to the tumor grafts were similar to 
the ones detected by the Landsteiner’s hemagglutination reactions. Moreover, he suspected 
these antigens were present in normal tissues and not just in tumor tissues (Klein, 1986a).  
He left the inbred mice and idea for Gorer to pursue. Using agglutination techniques in 
mice, Gorer, along with the Jackson Laboratory scientist George Snell, independently 
discovered the H-2 system, now more broadly known as the MHC (Gorer, 1936, 1937; 
Klein, 1986b). Eventually, George Snell, along with Baruj Benacerraf, discoverer of MHC 
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class II, and Jean Dausset, discoverer of the MHC in humans, would receive Noble Prizes 
in 1980 for their work. Peter Gorer unfortunately died in 1961 but, presumably, would have 
been included for his ground-breaking efforts. 
The discovery of the MHC attracted little attention until Peter Medawar, a physician 
assigned to work with burn victims during World War II, began studying why skin grafts 
failed. One of his first patients was a woman who had received two sets of skin grafts from 
the same donor. The first graft set initially healed but was later rejected but the replacement 
grafts were destroyed almost immediately. Medawar concluded that the tissue graft 
rejection is due to an immune response and that the antigens eliciting the reactions were 
the same as Gorer described. Medawar would go on to receive a Noble Prize in 1960 for 
this work (Klein, 1986a). 
The structural and functional complexity of the HLA molecule would take longer 
to unravel. An important piece of the puzzle and a new immunological paradigm was 
uncovered in 1974 by Zinkernagel and Doherty. At that time, it was established that HLA 
was important for transplantation but the physiological function of the molecule was 
unknown. Working with lymphocytic choriomeningitis (LCM) virus, Zinkernagel and 
Doherty discovered that lysis of the LCM-infected cell cultures only occurred when the 
target cell and the sensitized T cells shared at least one haplotype of H-2 antigens 
(Zinkernagel & Doherty, 1974a,b). Once again, the use of inbred-strain mice was crucial 
as it was observed that only some mouse strains were producing virus-specific cytotoxic T 
lymphocytes (Zinkernagel & Doherty, 1997). This became known as MHC restriction for 
which the research duo received the 1996 Noble Prize in Medicine. The mechanism behind 
MHC restriction wasn’t understood until crystal structures of the MHC were synthesized 
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in the late 1980s and revealed the presence of a bound peptide (Bjorkman et al., 1987a; 
Brown et al., 1988). The bound peptide is generally a self-peptide generated from within 
the cell but it may also be a foreign peptide from an infectious agent like LCMV. Thus, 
MHC restriction refers to the dual recognition of the self MHC along with the self or 
foreign bound peptide (Parham, 2005). 
 
1.1 Biology and Structure 
Human MHC genes are found in chromosome 6 and divided into three main 
regions, class I, class II, and class III, each encoding for structurally and functionally 
different molecules.  The class III region encodes for molecules involved in other immune 
functions, including complement, and will not be discussed at this time.  Overall, the MHC 
has 421 identifiable gene loci which encode for diverse proteins, most of which are 
involved in the immune response.  In addition to HLA class I, II, and III, the MHC encodes 
for other important proteins such as olfactory receptors, zinc finger, tumor necrosis factor, 
and heat shock proteins (Horton et al., 2004).  Classes I and II may be further sorted into 
classical loci important for transplantation due to their high level of polymorphism:  Class 
I includes HLA-A, B, and C.  Class II includes HLA-DRB, DQ, and DP (Rodey, 2000). 
Nonclassical class I and class II molecules are non- or oligo-morphic, and usually do not 
influence transplantation.       
Class I is made up of a transmembrane alpha chain and a soluble beta2 
microglobulin chain.  The alpha chain forms the peptide binding groove composed of two 
alpha helices on a beta-pleated sheet platform (Bjorkman et al., 1987b).  Together, the HLA 
and the peptide interact with the T cell receptor.  The class I associated peptide is an 
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endogenously generated molecule that arises from within the cell, thereby providing a form 
of immune surveillance of the intracellular environment.  HLA molecules paired with self-
peptides normally do not elicit a T-cell response, but in the case of infection, viral peptides 
are also presented.  In this scenario, cytotoxic T lymphocytes (CTL) recognize the peptide 
as foreign and destroy or lyse the infected cell (Abbas, 2012).   
The class II HLA molecule differs in that it is composed of two transmembrane 
alpha and beta chains and unlike the class I molecule’s ubiquitous presence on all nucleated 
cells, class II molecules are only found on dendritic cells, activated B cells and a few other 
specialized antigen-presenting immune cells.  The alpha and beta chain join together to 
form the antigen binding groove (Brown et al., 1993).  The class II peptide provides 
immune surveillance of the extracellular environment.  Once displayed on the class II 
molecule, a T cell will recognize the peptide as foreign but rather than destroying the cell 
via a cytotoxic immune response, the T cell will interact with other lymphocytes such a B 
cells to generate antibodies against the foreign antigens (Abbas, 2012). 
 
1.2 Polymorphism 
As previously discussed, both class I and II molecules have a peptide-binding 
groove.  Because the HLA molecule must be able to hold a large number of self and foreign 
peptides, the exons encoding the region around peptide groove are some of the most 
polymorphic genetics regions (Mungall et al., 2003).  This degree of polymorphism is vital 
for generating the immune response to infection and likely arose as the result of pathogen-
driven natural selection (Prugnolle et al., 2005).  More specifically, the greatest 
polymorphism is found in the sites that interact with the self-peptide.  This corresponds to 
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exons 2 and 3 for class I and exon 2 for class II.  Traditional HLA genotyping methods, 
which will be discussed later, have focused on the protein and genetic differences in these 
exons.  To date, over 15,000 HLA alleles have been identified (Robinson et al., 2015) and 
this number continues to grow rapidly as technological advances in sequencing have led to 
the interrogation of exons that encode for regions outside the peptide groove.  In addition, 
these same advances now permit genetic sequencing of the intronic regions.  It is now 
estimated that each HLA locus may harbor close to 3.5 million possible rare alleles (Klitz, 
Hedrick, & Louis, 2012). 
Some of the HLA alleles are disease associated.  For example, HLA alleles are 
associated with a number of autoimmune diseases such as celiac disease, narcolepsy, 
multiple sclerosis, rheumatoid arthritis, Type I diabetes and ankylosing spondylitis 
(Howell, 2014).  Some HLA alleles are associated with increased susceptibilities to 
infections or may dramatically affect the course of infection (HIV, leprosy, leishmaniasis, 
hepatitis B, hepatitis C, and human papilloma virus; Karlsson, 2014).  More recently, it has 
been shown that some drugs can bind noncovalently to certain HLA class I alleles and 
initiate T cell activation (Illing et al., 2012; Ostrov et al., 2012).  For example, the presence 
of HLA-B*57:01 can cause the potentially fatal hypersensitivity response to abacavir.  
Similarly, HLA-B*15:02 is associated with carbarmazepine hypersensitivity (Profaizer & 
Eckels, 2012).  The FDA now recommends HLA genotyping before patients undergo 






1.3 Genotyping for HLA 
There are numerous indications for performing HLA genotyping such as disease 
association testing.  However, the primary reason for genotyping is to mitigate rejection in 
solid organ and hematopoietic stem cell transplantation (HSCT).  Rejection may occur 
when recipient T cells recognize either the foreign HLA antigen (direct recognition) or the 
donor-derived peptides bound to recipient HLA molecule (indirect recognition; Abbas, 
2012).  Numerous studies have been done showing the benefits of HLA matching (Lee, 
2007; Petersdorf et al., 2001; Susal & Opelz, 2013). 
HLA genotyping and histocompatibility testing consists of identifying donor and 
recipient HLA alleles, testing for the presence of preformed HLA antibodies, and finally, 
performing a crossmatch between the recipient sera and donor cells.  Preformed HLA 
antibodies arise due to previous blood transfusions, pregnancy, or previous transplants.  
Ideally, all donor organs would be HLA-identical to the recipient but the vast number of 
HLA allelic specificities and shortage of donor organs makes this all but impossible.  
Therefore, HLA matching is the avoidance of donor organs that share the same HLA 
specificity of any antibodies that the recipient has formed.  The exception is HSCT in which 
the donor and recipient HLA type must be nearly identical.  
To address the problem of vast HLA polymorphism and many newly discovered 
alleles, the American Society for Histocompatibility and Immunogenetics (ASHI) created 
an ad-hoc committee to address the issue of minimal typing requirements.  Examining 
population data, the committee established the Common and Well-Documented (CWD) 
list of alleles that must be fully resolved (Cano et al., 2007; Mack et al., 2013).  Alleles that 
are “common” have an allele frequency of >0.001 in a reference population of at least 1500 
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individuals.  Well-documented alleles have been observed at least 5 times in unrelated 
individuals or have been observed 3 times in a specific haplotype (Mack et al., 2013).  High 
resolution genotyping is indicated by a minimum of four digits after the gene name (e.g., 
HLA-B*35:03), also known as two-field resolution (see Figure 1.1 for explanation of HLA 
nomenclature).  Genotyping for HSCT donors and recipients should consist of minimum 
of two-field resolution and no CWD allele ambiguities present.   
 
1.4 Complement-Dependent Cytotoxicity (CDC) Assay 
There are numerous challenges in HLA genotyping.  Individuals inherit one set, 
haploid genotype (or haplotype), of HLA genes from each parent.  HLA alleles are co-
dominantly expressed and quite polymorphic, thus, no wild type exists in HLA.  The 
earliest genotyping method was the cytotoxicity test, first developed by Peter Gorer in 1956 
(Klein, 1986b).  This test, with subsequent modifications, would be the standby test until 
the advent of molecular methods in the early 1990s.  As previously stated, human 
individuals do not have antibodies to HLA antigens unless they have been previously 
transfused, transplanted, or been pregnant.  Jean Dausset first studied agglutination of 
erythrocytes in humans using sera from patients who had received multiple blood 
transfusions (Klein, 1986a).  This observation was the first evidence of the human MHC.  
The discovery of alloantibodies in pregnant women was later observed by Rose Payne 
(Klein, 1986a; Payne, 1962) and another scientist, Jon van Rood, who proved the 
antibodies were against the paternal HLA type (Van Rood, Eernisse, & Van Leeuwen, 
1958).  Maternal allosensitization occurs during delivery as the placenta becomes detached 










turn, the maternal immune system recognizes and forms antibodies against the paternal 
HLA antigens. Characterization of the sera is important to determine its HLA specificity. 
The value of the multiparous antisera became quickly recognized and soon trading of sera 
across the world became commonplace as scientists began hunting for new antigens (Eng 
& Leffell, 2011).   
The complement-dependent cytotoxicity (CDC) test became widespread with the 
development of the microtoxicity assay by Terasaki (Terasaki & McClelland, 1964). This 
modification was significant in that only one microliter of antisera was required, thereby 
reducing the amount of valuable well-characterized antisera needed. Briefly, the assay 
consists of mixing one microliter of antisera with one microliter of lymphocytes. The 
lymphocytes are isolated from peripheral blood, lymph nodes, or splenic tissue. After an 
incubation step, rabbit serum is added to the reaction as a source of complement to increase 
the sensitivity of the assay. As the HLA antibodies bind to the cell surface, complement is 
activated and cell death occurs. After another incubation step followed by the addition of 
a supravital stain such as ethidium bromide or carboxymethylfluorescein, the cells are 
assessed microscopically for cell death. When more than 25% of the tested cells are dead, 
the cells are considered to share the complementary HLA antigen (Rodey, 2000).  
The CDC assay is relatively easy and quick to perform but numerous shortcomings 
limit its usefulness (see Table 1.1). As previously mentioned, the antisera must be well-
characterized in how well it will react with the multitude of HLA antigens. Several antigens 
share common epitopes, often called public epitopes, and it is a common occurrence for 
antibodies to be formed against these cross-reactive groups thus forming public antibodies 




Table 1.1. Advantages and Disadvantages of the CDC Assay. 
Complement-Dependent Cytotoxicity Assay 
Advantages 
 Relatively quick and easy to perform. 
 Can determine if null antigens are present 
if family studies are available. 
Disadvantages 
 Need well-characterized antisera.  
Antibodies need to be specific for a few 
HLA antigens. 
 Requires a large number of viable 
lymphocytes. 
 Complement must not have too much lytic 
potential.  Cell death should only occur in 
cells with corresponding HLA specificity. 
 Antisera generally only against broad 
specificities; allele-specific antibodies are 
rare and difficult to find. 
 Interpretation of cell death is subjective. 
 Cannot determine if HLA antigen is 
homozygous unless family studies are 
conducted. 





antigens and care must be taken to use a panel of antisera that contains a variety of public 
and private specificities to aid in interpretation.  The source and lot of complement is 
another area for concern.  Rabbit serum has traditionally been used as a source of 
complement, but typically individual lots of commercially available sera vary in reactivity.  
Therefore, careful titration experiments must be performed before purchase to ensure that 
the serum is not overly reactive.  Rabbit sera (and other mammalian sera) contain 
heterophilic antibodies that will react to all human cells (Rodey, 2000) and a high titer of 
heterophilic antibodies can mask the effect of the antisera and obscure the true HLA 
genotype by indiscriminately killing cells.  For this reason, plus the requirement by the 
National Marrow Donor Program (NMDP) for high-resolution genotyping and the 
commercial availability of DNA genotyping kits, genotyping by CDC has largely fallen 
out of favor.     
 
1.5 DNA Methods 
The lack of reproducibility and the need for the variable biological reagents such 
as antisera and complement place serological assays at a disadvantage.  The first DNA-
based assay for HLA typing was the restriction fragment length polymorphism (RFLP) 
assay (Le Gall et al., 1986) but was difficult to perform and prone to technical difficulties 
(Rodey, 2000).  The advent of the polymerase chain reaction in 1987 (Mullis & Faloona, 
1987) revolutionized the field and, for the first time, a more reproducible and standardized 
method for HLA genotyping was available.  The main PCR-based assays used for HLA 
genotyping are sequence-specific primers (SSP), sequence-specific oligonucleotide probe 
(SSOP) hybridization, and the Sanger sequence-based typing (SBT) assays.  The Sanger 
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SBT method will be discussed in a separate section.     
The sequence-specific primer (SSP) assay is the most simple of the molecular 
assays.  Briefly, primers are designed to hybridize to only one HLA allele or to a group of 
similar alleles (Olerup & Zetterquist, 1991). Following completion of PCR, the individual 
reaction products are added to an agarose gel and electrophoresis is performed.  The larger 
sized amplicons move more slowly through the gel as opposed to shorter sized ones.  
Therefore, HLA alleles can be assigned based on the presence of the correct sized band.  
This assay is easy to perform but can be tedious due to the large number of individual 
reactions that must be prepared.  Furthermore, it is difficult to perform on more than a few 
samples at any one time thereby limiting its usage to smaller labs. 
The sequence-specific oligonucleotide probe (SSOP) hybridization assay is better 
for allelic resolution because rather than using individual primers to isolate specific alleles, 
entire exons are amplified by generic primers (Table 1.2).  Following PCR, biotin-labeled 
probes are hybridized to the regions of interest. Following a wash step to remove any 
unbound probes, the samples are labeled with a chemoluminescent substrate that has been 
conjugated to a streptavidin molecule (Erlich, Opelz, & Hansen, 2001).  There are a number 
of modifications to this protocol depending upon the manufacturer.   For example, in early 
SSOP assays, the probes were physically bound to a nylon or nitrocellulose membrane 
(Saiki, Walsh, Levenson, & Erlich, 1989).  More recently, the use of color-coded 
microspheres coated with individual DNA probes for use on the Luminex instrument have 
gained popularity for their ease of use and scalability (Dunbar, 2006).  In this modification, 
the probes are labeled with biotin and the microspheres have replaced the nylon or 
methylcellulose membrane (Itoh et al., 2005).  The Luminex instrument uses two fixed 
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Table 1.2. Advantages and Disadvantages of SSP and SSOP Assays. 
PCR-Based Assays: SSP and SSOP 
Advantages 
 Chemically synthesized reagents improve 
standardization and reproducibility. 
 Smaller amounts of sample required.  Can 
be from any source where DNA can be 
extracted. 
 More complete genotyping assignment 
based on nucleic acid sequence, not 
protein sequence. 
 Increased sensitivity and specificity. 
 SSOP suitable for large numbers of 
samples. 
Disadvantages 
 Time consuming. 
 Expensive laboratory equipment may be 
required. 
 Low allelic resolution and thus more 
ambiguities. 





wavelength lasers, one to characterize the microsphere, based on its pattern of color 
fluorescence, and the other laser measures the amount of fluorescent antibody, or bound 
probe, on the surface of the microsphere (Dunbar, 2006). 
The Luminex SSOP assay is well-suited for handling large numbers of samples.  
While theoretically the number of probes is limitless, there is a physical limitation to the 
amount of spectral separation between the beads.  The original Luminex instrument could 
distinguish between 100 individual microspheres, but recently Luminex introduced the 
Flexmap 3D, which can discriminate between 500 uniquely labeled microspheres 
(Luminex, n.d.).  Regardless, the vast polymorphism of HLA greatly exceeds the 
capabilities of SSO.   
 
1.6 Sanger Sequencing 
Sequence-based typing (SBT) became a possibility in 1977 when Fred Sanger and 
colleagues developed a method to determine actual genetic sequences.  It is based on the 
principle of using chain-terminating dideoxynucleotides (ddNTP) to effectively halt the 
addition of nucleotides by the polymerase.  The ddNTP is a deoxynucleotide that has been 
chemically altered to lack the 3’-OH group required for the addition of the next nucleotide 
via formation of a phosphodiester bond (Sanger, Nicklen, & Coulson, 1977).  Initially, 
nucleotide labeling was done with 32P but was later replaced with a fluorescent dye, 
making the assay less hazardous and more economical (Smith et al., 1986).   In addition to 
the four ddNTPs, the reaction master mix contains a mix of unaltered 
deoxynucleosidetriphosphates (dNTPs).  The reaction proceeds as incoming dNTPs are 
incorporated into the growing DNA chain.  Each time a ddNTP is incorporated, the chain 
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ends and the fragment is labeled with a fluorescent tag unique to the individual nucleotide 
incorporated.  After sequencing, the products are size separated using capillary 
electrophoresis.  Shorter fragments migrate faster.  The sequence is then read from the 
bottom to the top of the gel (Buckingham, 2012).  Development of automated sequencers 
which use raster scanning lasers to capture the fluorescent wavelengths of the individual 
fragments have reduced the need for the manual reading of gels and improved the 
scalability of the method.  These improvements have decreased errors and increased the 
run-throughput of the assay (Mardis, 2013).               
Sanger sequencing for HLA typing is considered to be the gold standard for 
obtaining high resolution genotyping.  Typically, SSP or SSOP methods do not achieve 
typing resolution that is free of CWD ambiguities.  As previously discussed, the number 
of HLA alleles continues to grow as more individuals and regions outside of exons 2 and 
3 are sequenced.  Furthermore, it is economically and technologically tenuous to resolve 
every allele using either SSP or SSOP.  Fortunately, Sanger sequencing is able to resolve 
several CWD ambiguities and has been the method of choice for genotyping donors and 
recipients for HSCT.  Nevertheless, there are some shortcomings (Table 1.3).  
One of the major drawbacks to Sanger sequencing is that it is inherently qualitative.  
While the size of the electropherogram peak is representative of the number of copies of a 
nucleotide observed, it is semiquantitative at best (see Figure 1.2; Voelkerding, Dames, & 
Durtschi, 2010).   
Read-length or the length of the actual DNA sequence is limited to less than 1000 
bp due to physical limitations of the method, including matrix of the polyacrylamide gel or 
capillary, or electrophoresis conditions preventing longer reads from being sequenced 
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Table 1.3. Advantages and Disadvantages of Sanger Sequencing for HLA Genotyping. 
Sanger Sequencing 
Advantages 
 Numerous commercial kits available.  
 Widespread usage and experience. 
 High-resolution HLA genotyping. 
Disadvantages 
 Cannot resolve cis/trans ambiguities. 










Figure 1.2. Sanger Electropherogram. Each base is color-coded: C = blue, G = black, A = 
green, T = red.  One individual peak indicates the sequence is homozygous at that position.  
A heterozygous position is indicated by the presence of two peaks.  In this example, the 
first heterozygous position shows overlapping G and A peaks.  The second heterozygous 
position shows overlapping T and A peaks.  Both complementary strands of DNA are 








 (Mardis, 2013).   
There are three main causes of allelic ambiguities in SBT (Voorter, Mulkers, 
Liebelt, Sleyster, & van den Berg-Loonen, 2007).  The first is when a polymorphism 
defining two alleles is outside the region sequenced.  Traditionally, only exons 2-3 are 
sequenced for class I, and only exon 2 is sequenced for class II.  A well-known example of 
this issue is DRB1*14:01 versus DRB1*14:54.  Both share the same sequence for exon 2 
but differ by one base in exon 3.  Since only exon 2 is sequenced, DRB1*14:54 samples 
are typed and reported as DRB1*14:01.  This is significant because allele frequency studies 
have shown that DRB1*14:54 is most often the correct allele because it has a much higher 
allele frequency (Xiao et al., 2009).   
The second cause is due to the lack of fully characterized HLA sequences in the 
international ImMunoGeneTics (IMGT) database.  It is estimated that less than 10% of the 
alleles have been completely sequenced from 3’ untranslated region to 5’ untranslated 
region (Lind et al., 2013).  It is very likely that as alleles are fully sequenced, more alleles 
will be discovered.   
Cis/trans or phase ambiguities are the third type of HLA ambiguity. These 
ambiguities may exist within a single exon or between exons.  In SBT, both heterozygous 
alleles are amplified and sequenced together. This can lead to multiple allele combinations 
that share the same base. Figure 1.3 is a simple representation of two chromosomes that 
are alike with the exception of the second polymorphic base.  Here, it is impossible to 
determine if the “T” variant is associated with either “G” or “A.” 
The Sanger electropherogram would display this scenario the same it would with 
any other heterozygous position as demonstrated in Figure 1.2. In that example, the first 
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heterozygous position is a G (guanine) and an A (adenine) and the second heterozygous 
position is C (cytosine) and A (adenine), however, it is impossible to determine from this 
sequence the correct pairing of these bases.  The first nucleotide G could pair with either 
A or C, and conversely A could pair with either A or C. Only by comparing the entire 
sequence against a reference sequence can the correct allele pair be determined. Figure 1.4 
is an example of a typical situation seen in HLA typing. Here, it is difficult to determine if 
the correct B locus pair is B*15:01, 35:01 or B*15:20, 35:43 because B*15:01 and B*15:20 
share the same sequence for exon 2 and B*15:01 and B*35:43 share the same sequence for 
exon 3. Since exons 2 and 3 are amplified and sequenced separately, resolution of these 
ambiguities is impossible.  Both B*15:20 or 35:43 are less frequently observed alleles, 
however, they still meet the criteria for inclusion on the CWD list and must be resolved. 
Resolution can be achieved by one of two methods.  The first is to use a group-specific 
sequencing primer to only amplify one allele group via SBT (see Figure 1.5).   
In this example, using a sequencing primer specific to exon 3 and B*08:01 (see 
arrow) would rule out the possibility of the B*07:05, 08:07 pair.  The other method to 
establish the correct allele pair is to sequence a fragment long enough to span 
polymorphisms in both exons.  This will be discussed further in the next section.  
Alternatively, resolution of CWD alleles may be done by genotyping the entire family. 
 
1.7 Next-Generation Sequencing (NGS) 
Next-generation sequencing (NGS) is the latest method applied for HLA typing and 
is poised to replace Sanger sequencing as the new gold standard.  NGS is a broad term used 




Reference   ATCTCCAACGC 
Chrom. 1     - G - - - - - - T - - 
Chrom. 2     - A - - - - - - T - - 
 
Figure 1.3. Cis/Trans Ambiguity Example. 
 
 
Figure 1.4. Phasing in HLA. 
 
 




sequencing because each fragment is individually amplified and sequenced in a digital 
fashion (Mardis, 2013).  This massively parallel manner is what makes NGS quantitative.  
There are several NGS platforms available, however, only Illumina’s proprietary 
technology, sequencing by synthesis, will be discussed in this thesis.  The Illumina MiSeq 
was selected as our instrument of choice because of its low error rate in comparison to 
other platforms (De Santis et al., 2013).  The general steps for HLA NGS are listed in Table 
1.4.         
The process starts with long-range PCR.  For HLA-A, B, and C, the entire gene is 
sequenced.  DRB1 has a large intron 1 making long range PCR difficult; therefore, only 
exons 2 through 4 are amplified.  After amplification, construction of the DNA library 
begins with the shearing of the large amplicon to create random, overlapping DNA 
fragments of varying lengths.  Two main methods are used to break up the large DNA 
amplicons: sonication or enzymes (Voelkerding et al., 2010).  The resulting fragments have 
large overhangs and require repair work on both the 3’ and 5’ ends to either blunt or fill in 
the DNA strands as needed.  Monoadenylation of the 3’ end prepares the fragment for the 
addition of a synthetic adaptor that is specific to the DNA oligo on the Illumina flow cell 
(Mardis, 2013).  Molecular barcodes, unique to each individual sample, are added at this 
stage, enabling the pooling of multiple samples together.  This feature facilitates more 
efficient usage of the high-throughput capabilities of the Illumina sequencer.  After a series 
of clean-up steps, the final DNA library is quantified and adjusted to the correct 
concentration in preparation for cluster generation and sequencing by synthesis on the 
Illumina MiSeq.   
The massively parallel feature of NGS occurs during cluster generation.  After the 
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Table 1.4. General Steps Required for HLA Genotyping by NGS. 
General Steps Required for HLA Genotyping by NGS 
Long-range PCR 
Library Construction 
 Quantification of amplicons 
 Fragmentation 
 End-repair and monoadenylation 
 Ligation of Illumina-specific adaptors 
 Ligation of unique molecular bar code to each sample 
 Size selection 
 Clean-up 
 Final pooling and quantification 
Cluster generation on the Illumina MiSeq 







pooled library has been added to the MiSeq Reagent cartridge, the DNA libraries 
individually hybridize to oligos on the flow cell (see Figure 1.6).  The Illumina flow cell 
consists of a glass slide upon which oligos, complementary to the DNA library adaptors, 
have been covalently attached (Metzker, 2010).  Once bound, the individual fragments are 
amplified using isothermal bridge amplification in order to create clusters of cloned 
fragments (Voelkerding et al., 2010).  The oligos are spatially separated so that any DNA 
library that attaches remains at that physical location during the entire sequencing process 
(Shendure & Ji, 2008). 
After bridge amplification, the clusters are ready for sequencing.  The DNA library 
adaptors also contain genetic regions that are complementary to the primers required for 
initiation of sequencing.  Sanger sequencing relies on the use of altered nucleotides which 
lack the 3’ -OH group.  Incorporation of the dideoxynucleotides stops the reaction.  In 
contrast, the Illumina method makes use of reversible terminators.  The nucleotides contain 
an identifying fluorescent dye and a unique blocking group at the 3’ -OH position (Bentley 
et al., 2008).  After incorporation of the complementary altered nucleotide to the cluster 
template, the remaining nucleotides are washed away.  An image is taken to determine the 
identity of the new nucleotide before the addition of tris(2-carboxyethyl) phosphine 
(TCEP) to remove the fluorescent moiety and regenerate the 3’-OH group in order to 
prepare for the addition of the next cycle of nucleotides (Bentley et al., 2008; Metzker, 
2010).  A distinguishing feature of massively parallel sequencing is that the sequencing 
reaction is executed in a nucleotide-by-nucleotide manner in contrast to the detached 
separation and detection of previously sequenced Sanger reaction products (Mardis, 2011).   









can be “tiled’ across the length of the gene (see Figure 1.7). 
 
1.8 HLA Genotyping by NGS: The New Gold Standard 
HLA genotyping by NGS will become the new gold standard for the following 
reasons.  First, the entire gene is interrogated as opposed to a few exons. This permits 
greater resolution of known polymorphisms outside of exon 2. For example, distinguishing 
between DRB1*14:01 and DRB1*14:54 is not an issue with NGS, since exon 3 will be 
sequenced. However, the lack of full sequences in the IMGT Database remains a large, but 
not insurmountable, problem as the expense of whole gene sequencing is becoming cost 
effective with NGS. Eventually, the missing genetic sequences in the IMGT database will 
be completed. One outstanding question about high-resolution genotyping is that it may 
not affect clinical outcomes. A recent study involving a small number of HSCT patients 
who had their HLA genotyping performed by NGS, found that alleles with exonic 
mismatches outside the antigen recognition site were not shown to affect transplant 
outcomes (Hou et al., 2016). Further retrospective studies with larger numbers of patients 
will be required to definitively answer this question. Regardless, the final reason NGS will 
become the new gold standard is because high-resolution genotyping can be achieved 
easily without the need for additional time and laboratory resources to resolve CWD alleles 
or to meet minimal NMDP typing requirements.  Even with Sanger sequencing, it is not 
uncommon for additional testing to be done in order to satisfy these requirements.  This 
leads to the delayed reporting of results and requires that additional reagents such as group-
specific primers be kept on hand.  The additional reagents require the same quality control 
measures and proficiency testing as required by normal laboratory procedures.  High-
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resolution genotyping is achieved by a combination of NGS-specific approaches: 
quantification of cloned fragments, phasing of the entire gene, and paired end sequencing.  
Examples of quantified fragments and phasing are shown in Figure 1.7.   
In Figure 1.7, the alignment of fragments against HLA-A for the last part of intron 
1 through exon 3 are displayed.  The vertical colored bars in each read represent bases that 
are not in agreement with the reference sequence.  The pink and yellow reads represent 
forward and reverse strand reads.  Through random fragmentation and the clonal 
amplification of individual fragments, over-lapping and multiple copies can be aligned to 
the reference allele across the gene.  It is through this strategy the entire gene has the 
potential to be fully linked or phased.  As the process is quantitative, the number of times 
a nucleotide base is sequenced is known as the depth of coverage (Voelkerding et al., 2010).  
This is of particular importance in HLA where individuals are typically heterozygous and 
have numerous polymorphisms.  Unfortunately, errors in sequencing do occur and it is 
impossible to distinguish an error from a polymorphism, therefore, having a sufficient 
depth of coverage is important to determine the true base call (Sims, Sudbery, Ilott, Heger, 
& Ponting, 2014).  Figure 1.8 shows an example of a sequencing error.  Arrows point to 
two positions that are not in agreement with the reference sequence.    
Since most individuals are heterozygous, the minimum and average depths of 
coverage are crucial quality metrics to ensure that both alleles are balanced in the number 
of times that they are sequenced.  For example, each heterozygous allele should each have 
50% of the total reads (Voelkerding et al., 2010).   
The correct size distribution of the DNA fragments is crucial for phasing.  














there are many repetitive elements (Voelkerding et al., 2010) but long fragments are more 
difficult to create and size select in the library construction process.  Furthermore, the 
signal-to-noise ratio limits both the fragment size and read-length for the Illumina 
sequencers (Mardis, 2013).  The ideal fragment size is long enough to span and link 
polymorphism across exons and introns in order to eliminate cis/trans ambiguities.  In 
tandem with fragment size, the reagent kit read-length must be considered.  Each Illumina 
reagent kit contains a limited amount of reagents to produce a set number of cycles or 
number of times an individual nucleotide is added to the DNA template.  In the work that 
follows, 300, 500, and 600 bp cycle (or read-length) kits are evaluated and compared.  
Using a 600 bp read-length kit with fragments less than 200 bp is an inefficient use of the 
kit and its reagents.  Therefore, identifying the intersection of ideal fragment size with read-
length is important for complete phasing. Finally, paired-end sequencing is a unique feature 
of NGS and serves to improve overall sequencing confidence because each cluster is 
sequenced from both ends, thus creating two reads for one fragment (Coonrod, Durtschi, 
Margraf, & Voelkerding, 2013).  Through the unique features of NGS, high-resolution 
genotyping can be achieved in just one assay as opposed to several assays as often, 
currently required. Table 1.5 lists the advantages and disadvantages of Illumina-based 
NGS. 
 
1.9 Specific Aims of Research 
Based on its success in genetic testing, NGS technology has the potential to resolve 
long standing problems associated with HLA genotyping, therefore we hypothesized that  




Table 1.5. Advantages and Disadvantages of NGS (Illumina). 
NGS Sequencing 
Advantages 
 Interrogates the entire gene (with some 
exceptions). 




 Requires large capital equipment 
purchases. 
 Short read length (< 600 bp). 
 Significant hands-on time required for 





unambiguous results than Sanger sequencing without the need for reflex testing.  This 
project arose before commercial kits became available and there were several unanswered 
questions.  Using off-the -shelf reagents, we sought to determine if we could obtain 
accurate HLA genotyping on 10 well-characterized samples from the International 
Histocompatibility Working Group (IHWG) using the Illumina MiSeq. 
1. One of the most important questions was if all 5 loci (HLA-A, B, C, DRB1, 
and DQB1) could be indexed for the same sample (index-by-patient) or if each amplicon 
required individual indexing (index-by-amplicon).  HLA loci are homologous due to their 
origin via gene duplication events (Parham, 1999).  We sought to know if this homology 
would impede accurate genotyping assignments particularly in samples indexed as a whole 
as opposed to individually indexing each locus.  This is critical for clinical testing, as 
indexing-by-amplicon is far more costly than indexing-by-patient.  
2. Part of ensuring that phasing is made across the entire gene, the ideal 
fragment size of the DNA library must be determined.  Ideally, DNA fragments are long 
enough to span distant polymorphisms in order to resolve cis/trans ambiguities.  Fragments 
too short will prevent phasing but fragments too long will interfere with cluster generation. 
We begin with a simple comparison of two fragment sizes, 100-300 bp and 300-600 bp.  
These same libraries were compared using two different read-length MiSeq reagent kits, 
2x150 and 2x250.  Ten IHWG samples were compared to determine best indexing strategy, 
fragment length size, and read-length kit. Figure 1.9 is a flowchart of our comparisons. The 
experiments used to answer these questions and the subsequent results can be found in 
Chapter 2. 






























All above groups are sequenced on 2x150 MiSeq read-length kit 
All above groups are sequenced on 2x250 MiSeq read-length kit 
Perform long-range PCR for HLA-A, B, C, DRB1 and DQB1 

























Figure 1.10. Flowchart of Chapter 3 Experiments to Determine Optimal Fragment Size and 
Read-Length Kit for the In-House Method.  








           All above groups are sequenced on 2x250 MiSeq read-length kit. 


























fragment sizes are expanded up to 1200 bp and an additional MiSeq read-length kit is 
evaluated, 2x300 bp.  Early on, it was observed that the AMPure beads could not size-
select libraries greater than 900 bp.  Therefore, three size-selection strategies were 
investigated and compared for the 600-900 bp fragment groups: no-size selection, AMPure 
beads, and an automated gel electrophoresis method—the Sage Science PippinPrep.  The 
same 10 IHWG samples are used throughout.  From this work, we establish the optimal 
conditions for performing the in-house HLA NGS assay. 
4. Finally, two newly available commercial kits, the Omixon Holotype X2 
24/7, and the Illumina HLA TruSight, are evaluated and compared against the optimized 
in-house conditions.  This is done by using 38 deidentified clinical samples from the 
Histocompatibility and Immunogenetics Laboratory at the University of Utah.  These 
samples have been HLA typed by Sanger sequencing and consist of DNA from 
hematopoietic stem cell transplant donors and recipients.  This comparison will examine 
over-all typing accuracy, allele-resolution, and ease of work-flow. Chapter 4 is the 





Abbas, A. K., Lichtman, A., & Pillai, S. (2012). Cellular and molecular immunology. 
Philadelphia, PA: Elsevier. 
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. 
G., . . . Smith, A. J. (2008). Accurate whole human genome sequencing using 
reversible terminator chemistry. Nature, 456(7218), 53-59. 
doi:10.1038/nature07517 
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & Wiley, 
D. C. (1987a). The foreign antigen binding site and T cell recognition regions of 
class I histocompatibility antigens. Nature, 329(6139), 512-518.  
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & Wiley, 
D. C. (1987b). Structure of the human class I histocompatibility antigen, HLA-
A2. Nature, 329(6139), 506-512.  
Brown, J. H., Jardetzky, T., Saper, M. A., Samraoui, B., Bjorkman, P. J., & Wiley, D. C. 
(1988). A hypothetical model of the foreign antigen binding site of class II 
histocompatibility molecules. Nature, 332(6167), 845-850.  
Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L., 
& Wiley, D. C. (1993). Three-dimensional structure of the human class II 
histocompatibility antigen HLA-DR1. Nature, 364(6432), 33-39.  
Buckingham, L. (2012). Molecular diagnostics (2nd ed.). Philadelphia, PA: F.A Davis 
Company. 
Cano, P., Klitz, W., Mack, S. J., Maiers, M., Marsh, S. G., Noreen, H., . . . Fernandez-
Vina, M. (2007). Common and well-documented HLA alleles: Report of the ad-
hoc committee of the American Society for Histocompatiblity and 
Immunogenetics. Human Immunology, 68(5), 392-417. 
doi:10.1016/j.humimm.2007.01.014 
Coonrod, E. M., Durtschi, J. D., Margraf, R. L., & Voelkerding, K. V. (2013). 
Developing genome and exome sequencing for candidate gene identification in 
inherited disorders: An integrated technical and bioinformatics approach. 
Archives of Pathology & Laboratory Medicine, 137(3), 415-433. 
doi:10.5858/arpa.2012-0107-RA 
De Santis, D., Dinauer, D., Duke, J., Erlich, H. A., Holcomb, C. L., Lind, C., . . . Allcock, 
R. J. (2013). 16(th) IHIW: review of HLA typing by NGS. International Journal 
of Immunogenetics, 40(1), 72-76. doi:10.1111/iji.12024 
Dunbar, S. A. (2006). Applications of Luminex xMAP technology for rapid, high-




Eng, H. S., & Leffell, M. S. (2011). Histocompatibility testing after fifty years of 
transplantation. Journal of Immunological Methods, 369(1-2), 1-21. 
doi:10.1016/j.jim.2011.04.005 
Erlich, H. A., Opelz, G., & Hansen, J. (2001). HLA DNA typing and transplantation. 
Immunity, 14(4), 347-356. doi:http://dx.doi.org/10.1016/S1074-7613(01)00115-7 
Gorer, P. A. (1936). The detection of antigenic differences in mouse erythrocytes by the 
employment of immune sera. British Journal of Experimental Pathology, 17, 42-
50.  
Gorer, P. A. (1937). The genetic and antigenic basis of tumour transplantation. Journal of 
Pathology and Bacteriology, 44, 691-697.  
Horton, R., Wilming, L., Rand, V., Lovering, R. C., Bruford, E. A., Khodiyar, V. K., . . . 
Beck, S. (2004). Gene map of the extended human MHC. Nature Reviews 
Genetics, 5(12), 889-899. doi:10.1038/nrg1489 
Hou, L., Vierra-Green, C., Lazaro, A., Brady, C., Haagenson, M., Spellman, S., & 
Hurley, C. K. (2016). Limited HLA sequence variation outside of antigen 
recognition domain exons of 360 10 of 10 matched unrelated hematopoietic stem 
cell transplant donor-recipient pairs. HLA, n/a-n/a. doi:10.1111/tan.12942 
Howell, W. M. (2014). HLA and disease: Guilt by association. International Journal of 
Immunogenetics, 41(1), 1-12. doi:10.1111/iji.12088 
Illing, P. T., Vivian, J. P., Dudek, N. L., Kostenko, L., Chen, Z., Bharadwaj, M., . . . 
McCluskey, J. (2012). Immune self-reactivity triggered by drug-modified HLA-
peptide repertoire. Nature, 486(7404), 554-558. doi:10.1038/nature11147 
Itoh, Y., Mizuki, N., Shimada, T., Azuma, F., Itakura, M., Kashiwase, K., . . . Inoko, H. 
(2005). High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a 
PCR-SSOP-Luminex method in the Japanese population. Immunogenetics, 
57(10), 717-729. doi:10.1007/s00251-005-0048-3 
Karlsson E. K, Kwiatkowski. D. P., Sabeta P.C. (2014). Natural selection and infectious 
disease in human populations. Nature Reviews Genetics, 15, 379-393.  
Klein, J. (1986a). Natural history of the major histocompatibility complex. New York, 
NY: John Wiley & Sons, Inc. 
Klein, J. (1986b). Seeds of time: Fifty years ago Peter A. Gorer discovered the H-2 
complex. Immunogenetics, 24(6), 331-338. doi:10.1007/bf00377947 
Klitz, W., Hedrick, P., & Louis, E. J. (2012). New reservoirs of HLA alleles: Pools of 




Le Gall, I., Chausse, A. M., Marcadet, A., Millasseau, P., Beaud'Huy-Lancelin, D., Font, 
M. P., . . . Massart, C.(1986). New methods for detection of HLA genes 
polymorphism useful for associated diseases studies. Pathologie Biologie (Paris), 
34(6), 801-807.  
Lee S. J., Klein. J., Haagenson, M., Baxter-Lowe, L. A., Confer, D. L., Eapen, M., 
Fernandez-Vina, M.,…Anasetti, C. (2007). High-resolution donor-recipient HLA 
matching contributes to the success of unrelated donor marrow transplantation. 
Blood, 2007(110), 4576-4583.  
Lind, C., Ferriola, D., Mackiewicz, K., Papazoglou, A., Sasson, A., & Monos, D. (2013). 
Filling the gaps - the generation of full genomic sequences for 15 common and 
well-documented HLA class I alleles using next-generation sequencing 
technology. Human Immunology, 74(3), 325-329. 
doi:10.1016/j.humimm.2012.12.007 
Little, C. C., & Tyzzer., E. E. (1916). Further studies on the inheritance of susceptibility 
to a transplantable tumor of the Japanese waltzing mouse. Journal of Medical 
Research, 33, 393-453.  
Luminex. (n.d.) Flexmap 3D [webpage]. Retrieved from 
https://www.luminexcorp.com/clinical/instruments/flexmap-3d/ 
Mack, S. J., Cano, P., Hollenbach, J. A., He, J., Hurley, C. K., Middleton, D., . . . 
Fernandez-Vina, M. (2013). Common and well-documented HLA alleles: 2012 
update to the CWD catalogue. Tissue Antigens, 81(4), 194-203. 
doi:10.1111/tan.12093 
Mardis, E. R. (2011). A decade's perspective on DNA sequencing technology. Nature, 
470(7333), 198-203. doi:10.1038/nature09796 
Mardis, E. R. (2013). Next-generation sequencing platforms. Annual Review of 
Analytical Chemistry (Palo Alto California), 6, 287-303. doi:10.1146/annurev-
anchem-062012-092628 
Metzker, M. L. (2010). Sequencing technologies - the next generation. Nature Reviews 
Genetics, 11(1), 31-46. doi:10.1038/nrg2626 
Mullis, K. B., & Faloona, F. A. (1987). Specific synthesis of DNA in vitro via a 
polymerase-catalyzed chain reaction. Methods in Enzymology, 155, 335-350.  
Mungall, A. J., Palmer, S. A., Sims, S. K., Edwards, C. A., Ashurst, J. L., Wilming, L., . . 
. Beck, S. (2003). The DNA sequence and analysis of human chromosome 6. 
Nature, 425(6960), 805-811. doi:10.1038/nature02055 
Olerup, O., & Zetterquist, H. (1991). HLA-DRB1*01 subtyping by allele-specific PCR 




Ostrov, D. A., Grant, B. J., Pompeu, Y. A., Sidney, J., Harndahl, M., Southwood, S., . . . 
Peters, B. (2012). Drug hypersensitivity caused by alteration of the MHC-
presented self-peptide repertoire. Proceedings of the National Academy of Science 
U S A, 109(25), 9959-9964. doi:10.1073/pnas.1207934109 
Parham, P. (1999). Virtual reality in the MHC. Immunological Reviews, 167, 5-15.  
Parham, P. (2005). Putting a face to MHC restriction. Journal of Immunology, 174(1), 3-
5.  
Payne, R. (1962). The development and persistence of leukoagglutinins in parous 
women. Blood, 19, 411-424.  
Petersdorf, E. W., Hansen, J. A., Martin, P. J., Woolfrey, A., Malkki, M., Gooley, T., . . . 
Anasetti, C. (2001). Major-histocompatibility-complex class I alleles and antigens 
in hematopoietic-cell transplantation. New England Journal of Medicine, 345(25), 
1794-1800. doi:10.1056/NEJMoa011826 
Profaizer, T., & Eckels, D. (2012). HLA alleles and drug hypersensitivity reactions. 
International Journal of Immunogenetics, 39(2), 99-105. doi:10.1111/j.1744-
313X.2011.01061.x 
Prugnolle, F., Manica, A., Charpentier, M., Guegan, J. F., Guernier, V., & Balloux, F. 
(2005). Pathogen-driven selection and worldwide HLA class I diversity. Current 
Biology, 15(11), 1022-1027. doi:10.1016/j.cub.2005.04.050 
Robinson, J., Halliwell, J. A., Hayhurst, J. D., Flicek, P., Parham, P., & Marsh, S. G. 
(2015). The IPD and IMGT/HLA database: Allele variant databases. Nucleic 
Acids Research, 43(Database issue), D423-431. doi:10.1093/nar/gku1161 
Rodey, G. E. (2000). HLA beyond tears. Hesperus, CO: De Novo, Inc. 
Saiki, R. K., Walsh, P. S., Levenson, C. H., & Erlich, H. A. (1989). Genetic analysis of 
amplified DNA with immobilized sequence-specific oligonucleotide probes. 
Proceedings of the National Academy of Science U S A, 86(16), 6230-6234.  
Sanger, F., Nicklen, S., & Coulson, A. R. (1977). DNA sequencing with chain-
terminating inhibitors. Proceedings of the National Academy of Science U S A, 
74(12), 5463-5467.  
Shendure, J., & Ji, H. (2008). Next-generation DNA sequencing. Nature Biotechnology, 
26(10), 1135-1145. doi:10.1038/nbt1486 
Sims, D., Sudbery, I., Ilott, N. E., Heger, A., & Ponting, C. P. (2014). Sequencing depth 
and coverage: Key considerations in genomic analyses. Nature Reviews Genetics, 
15(2), 121-132. doi:10.1038/nrg3642 
Smith, L. M., Sanders, J. Z., Kaiser, R. J., Hughes, P., Dodd, C., Connell, C. R., . . . 
38 
 
Hood, L. E. (1986). Fluorescence detection in automated DNA sequence analysis. 
Nature, 321(6071), 674-679.  
Susal, C., & Opelz, G. (2013). Current role of human leukocyte antigen matching in 
kidney transplantation. Current Opinion in Organ Transplant, 18(4), 438-444. 
doi:10.1097/MOT.0b013e3283636ddf 
Terasaki, P. I., & McClelland, J. D. (1964). Microdroplet assay of human serum 
cytotoxins. Nature, 204(4962), 998-1000.  
U.S. FDA. (2007). Information for healthcare professionals: Dangerous or even fatal skin 
reactions - carbamazepine.   Retrieved from 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatie
ntsandProviders/ucm124718.htm 
U.S. FDA. (2011). Guidelines for the use of antiretroviral agents in HIV-1-infected adults 
and adolescents. Retrieved from 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 
Van Rood, J. J., Eernisse, J. G., & Van Leeuwen, A. (1958). Leucocyte antibodies in sera 
from pregnant women. Nature, 181(4625), 1735-1736.  
Voelkerding, K. V., Dames, S., & Durtschi, J. D. (2010). Next generation sequencing for 
clinical diagnostics-principles and application to targeted resequencing for 
hypertrophic cardiomyopathy: A paper from the 2009 William Beaumont 
Hospital Symposium on Molecular Pathology. Journal of Molecular Diagnostics, 
12(5), 539-551. doi:10.2353/jmoldx.2010.100043 
Voorter, C. E., Mulkers, E., Liebelt, P., Sleyster, E., & van den Berg-Loonen, E. M. 
(2007). Reanalysis of sequence-based HLA-A, -B and -Cw typings: How 
ambiguous is today's SBT typing tomorrow. Tissue Antigens, 70(5), 383-389. 
doi:10.1111/j.1399-0039.2007.00921.x 
Xiao, Y., Lazaro, A. M., Masaberg, C., Haagenson, M., Vierra-Green, C., Spellman, S., . 
. . Hurley, C. K. (2009). Evaluating the potential impact of mismatches outside 
the antigen recognition site in unrelated hematopoietic stem cell transplantation: 
HLA-DRB1*1454 and DRB1*140101. Tissue Antigens, 73(6), 595-598. 
doi:10.1111/j.1399-0039.2009.01245.x 
Zinkernagel, R. M., & Doherty, P. C. (1974a). Immunological surveillance against 
altered self components by sensitized T lymphocytes in lymphocytes 
choriomeningitis. Nature, 251(5475), 547-548.  
Zinkernagel, R. M., & Doherty, P. C. (1974b). Restriction of in vitro T cell-mediated 
cytotoxicity in lymphocytic choriomeningitis within a syngeneic or 
semiallogeneic system. Nature, 248(5450), 701-702.  
Zinkernagel, R. M., & Doherty, P. C. (1997). The discovery of MHC restriction. 
39 
 














REPORT ON THE EFFECTS OF FRAGMENT SIZE, INDEXING, 




























HLA GENOTYPING IN THE CLINICAL LABORATORY: COMPARISON  










































The two peer-reviewed published manuscripts enclosed in this thesis, “Report on 
the effects of fragment size, indexing, and read length on HLA sequencing on the 
Illumina MiSeq” and “HLA genotyping in the clinical laboratory: Comparison of next-
generation sequencing methods” represent research to establish that NGS is the new gold 
standard for HLA genotyping. We showed that HLA Genotyping by NGS produces more 
correct and unambiguous results than Sanger sequencing without the need for reflex 
testing. 
NGS-based HLA typing presented here differs from Sanger sequencing in that the 
whole gene, or most of the gene, is sequenced.  Routine clinical Sanger sequencing only 
interrogates exons 2-4 for class I, and exon 2 for class II.  Table 4.1 compares regions 
sequenced between the three different methods.   
The ability to sequence more introns and exons represents an improvement over 
Sanger sequencing and, consequently, provides greater allelic resolution than previously 
possible.  As gaps in the IMGT database are filled, 3rd and 4th field allele resolution will 
be more readily attainable.  The Omixon Holotype kit did not include DPA1 typing when 
it was initially evaluated but recent updates to the kit include primers for DPA1.  No 
further work to accommodate additional loci has been done with the in-house kit.    
Our conclusion in Chapter 2 regarding indexing strategy was vital in showing that 
NGS can be more streamlined.  There, the index-by-amplicon and index-by-patient 
strategies were compared using the in-house method.  Both methods are equal in 
providing correct and unambiguous typing results.  It is noted in Chapter 3 that the 
Illumina HLA TruSight kit required an index-by-amplicon approach.  Some problems 




Table 4.1. Comparison of HLA Exons/Introns Sequenced by NGS.  
Target Sequence 
Loci Omixon Holotype X2 24/7 Illumina HLA TruSight In-House 
HLA-A Entire gene Entire gene Entire gene 
HLA-B Entire gene Entire gene Entire gene 
HLA-C Entire gene Entire gene Entire gene 
HLA-DRB1 Intron 1-exon 5 Exon 2-intron 4 Intron 1-intron 4 
HLA-DQB1 Entire gene (2 primer sets) Entire gene intron 1-intron 4 
HLA-DPB1 intron 1-3'UTR exon 2-3'UTR Not tested 
HLA-DQA1 Entire gene Entire gene Not tested 
HLA-DPA1 Not tested Entire gene Not tested 
 





physical strain due to manual pipetting.  Furthermore, there is a heightened potential for 
sample mix-up, therefore, the index-by-patient technique is the preferred and more 
economical method.     
The hallmark of NGS HLA genotyping is the achievement of high-resolution 
genotyping without the need for secondary testing.  This is accomplished through 
quantification of clonal DNA libraries, phasing, and paired-end sequencing to maximize 
confidence of alignment to the reference sequence.  This was demonstrated in chapters 
two and three.  Resolution of cis/trans ambiguities requires that the correct sized DNA 
library be used with the appropriate MiSeq read-length kit.  The average length of the 
HLA exons 2-4 is approximately 270 bp so it is advantageous to have an insert size larger 
than 270 bp in order to span across the exon and into the intron.  For the in-house 
method, 100-300 bp and 300-600 bp fragment libraries were initially compared.  Later, 
the limits of the in-house method’s fragmentase enzyme were explored in order to create 
larger fragments.  The constraints of AMPure beads for size selection required use of the 
PippinPrep for selection of the larger sized fragments.  In addition, a no-size selection 
library was examined.  The larger fragments compared included, 600-900 bp, 600-1200 
bp, 900-1200 bp fragments.  In the end, the 600-900 bp, PippinPrep size-selected library 
achieved the best resolution with 98% of all alleles typing correctly and unambiguously 
(Table 3.3). 
The Illumina read-length kit is important in the discussion of fragment size.  
Three MiSeq reagent kits were compared in the two papers, 2x150, 2x250, and 2x300 bp.  
The 2x150 bp kit was only evaluated in the first paper with the smaller fragments.  Use of 




to create the larger fragments would not result in any significant benefit.  However, with 
the longer fragments, the 2x250 read-length kit, and the use of the paired-end sequencing 
kits, distant polymorphisms can be spanned and complete phasing of the gene is 
accomplished.  Surprisingly, the larger 2x300 kit did not improve the overall correct and 
unambiguous typing rate.  It also required an additional 12 hours on the MiSeq 
instrument in comparison to the 2x250 kit.  Therefore, the 2x250 read-length kit was 
selected as the optimal read-length kit for the in-house method. 
Commercial HLA genotyping by NGS kits were not available at the time of initial 
research and development of the in-house method but later were released.  This 
development led to the comparison in Chapter 3 of two commercial kits, the Omixon 
24/7 Holotype and the Illumina HLA TruSight kits.  Both commercial assays were easy 
to execute but results were mixed (see Table 3.4).  Briefly, the Illumina HLA TruSight kit 
had the poorest performance with only 82.5% of all samples typing correctly and 
unambiguously for the second field.  Much of the poor performance is due to ambiguous 
DRB1 results.  This is due to the location of the forward primer.  Its placement, inside of 
the start of exon 2, prevents resolution of alleles that only differ in that position.  The 
Omixon Holotype X2 24/7 kit performed well with 95.6% of all samples typing correctly 
and unambiguously but the in-house method performed the best.  There, 97.6% of all 
samples typed correctly and unambiguously.   
An important metric for quality is the depth of coverage because redundancy in 
sequencing ensures confidence in alignment to the reference sequence.  Average 
coverages were between 70 and 697 for all three methods (Table 3.6).   DRB1 for the 




having low coverage.  The Omixon Twin software flags any sample with less than 25 
copies per base, suggesting that these samples be further investigated.   The in-house 
method had the highest overall coverage of 697.  This suggests that more patient samples 
could be added to flow cell making the assay more cost effective without sacrificing 
sequencing quality.    
An important consideration in kit selection is the workflow of the assay.  As 
previously stated, the efficacy of the index-by-patient approach was demonstrated by our 
studies in Chapter 2, yet the Illumina HLA TruSight kit still required the index-by-
amplicon approach.  This resulted in extra time, effort, and supplies.  The in-house 
method, despite the adoption of the index-by-patient strategy, has some drawbacks to its 
workflow.  Specifically, the number of clean-up steps required after each step of the 
library preparation process.  A consequence of the increased number of clean-up steps is 
the potential loss of DNA, increased labor time, manual pipetting, and increased pipette 
tip usage.  However, it is possible that this assay could be further optimized and the 
number of clean-up steps reduced.  Therefore, at this stage, the Omixon Holotype X2 
24/7 kit had the best performance with the easiest workflow to implement for clinical 
testing. 
We showed that HLA Genotyping by NGS produces more correct and 
unambiguous results than Sanger sequencing without the need for reflex testing.  Over 
97% of all samples were typed correctly and unambiguously without the need for 
reflexive testing using the in-house method.  Follow-up studies will include the 
evaluation of newer commercial kits as well as testing more HLA alleles. 
 
 
